A clinical study for evaluating efficacy and safety of long-term consumption -Double-blind, placebo-controlled parallel-group comparative, efficacy and safety of long-term verification study taking 1 times the dose of test food mainly composed of "ECM-E" that is an extract of chicken crests containing hyaluronic acid. - A clinical study for evaluating efficacy and safety of long-term consumption -Double-blind, placebo-controlled parallel-group comparative, efficacy and safety of long-term verification study taking 1 times the dose of test food mainly composed of "ECM-E" that is an extract of chicken crests containing hyaluronic acid.

Adaptgen Pharmaceutical Co., Ltd.0 个研究点目标入组 45 人开始时间: 2017年3月29日最近更新: 2023年10月17日

试验速览

暂无简介。

•The following exclusion criteria apply to subjects. 1) A person with the disease in gastrointestinal tract, liver, kidney, heart and circulatory system which have an influence on the absorption, distribution, metabolism and excretion of test food 2) A person with a major surgery history in the gastrointestinal tract sites such as gastrectomy, stomach and intestines suture, the intestinal resection (however, polypectomy, the a ppendectomy are excluded) 3) A person with a history of cerebrovasculardisorder (the asymptomatic lacunar infarct is excluded) 4) A person with tattoo which has an influence on the study because of its size or range 5) A person with hypersensitivity or idiosyncrasy, such as food allergy 6) A person who is suspected to have alcohol or drug dependence 7) A person who has participated in other clinical trials within 84 days from giving an informed consent 8) A person who donated 400 ml of blood within 84 days, 200 ml within 28 days, or a blood component (plasma or platelets) within 14 days from giving an informed consent 9) A nursing or pregnant woman 10) A person who is engaged in night duty 11) A person who has taken foods mainly composed of "ECM-E" within 28 days from the day that he/she gave an informed consent

发起方